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1. Introduction
Human papillomavirus (HPV)-associated disease is an important public health problem
worldwide. HPV is not only associated with 530,000 new cases of cervical cancer and
275,000 cervical cancer deaths worldwide each year but also causes vulvar, vaginal, anal,
and penile cancers as well as cervical and vulvar/vaginal precancerous lesions, genital
warts, and respiratory papillomatosis. Most individuals are not aware that they are infected
with HPV because of its subclinical or asymptomatic presentation, and thus, the virus can be
spread easily and unknowingly during sexual foreplay or sexual intercourse [1].
Cervical HPV infection is the most prevalent sexually transmitted disease [2]. HPV is so
common that more than half of all sexually active adults will be infected in their lifetime,
although young, sexually active women bear the brunt of both infection and clinical compli‐
cations. The Centers for Disease Control estimates that at least half of all sexually active in‐
dividuals will acquire HPV at some point in their lives, and at least 80% of women will
acquire an HPV infection by age 50 [3]. At least 50% of men will acquire a genital HPV infec‐
tion during their lifetime [1].
In 1995, the International Agency for Research on Cancer (IARC) first classified HPV types
16 and 18 as carcinogenic to humans, but based on more recent evidence, the list of carcino‐
genic HPV types has been expanded to include a total of 13 genital mucosotropic HPV types
as being definite or probable carcinogens (grade 1 or 2a) based on their frequent association
with invasive cervical cancer (ICC) (4). The causal role of HPV in all cancers of the uterine
cervix has been firmly established biologically and epidemiologically. The proteins of the
early genes E6 and E7 of the high-risk HPV types act as oncoproteins and play a key role in
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carcinogenesis [5]. HPV-16 and -18 account for approximately 70% of cancers of the cervix,
vagina, and anus and approximately 30–40% of cancers of the vulva, penis, and oropharynx.
Other cancers that are causally linked to HPV include non-melanoma skin cancer and cancer
of the conjunctiva. Although HR-HPV infection is a necessary cause of cervical cancer, it is
not a sufficient cause [6].
For the vast majority of people, these infections will be asymptomatic and will clear within
1–2 years [7-12]; however, a substantial increase in the risk for cervical cancer exists for
women who develop persistent infection with HR-HPV [13-16]. Infection with low oncogen‐
ic risk HPV types (LR-HPV) is also responsible for considerable morbidity associated with
benign lesions known as condyloma acuminata (genital warts) and a proportion of low-
grade squamous intraepithelial cervical lesions [17-19].
Because cervical cancer affects relatively young women, it represents the single biggest
cause of years of life lost (YLL) from cancer in the developing world, contributing more to
this burden of disease measure than tuberculosis, maternal conditions or acquired immuno‐
deficiency syndrome (AIDS). In developed countries, Papanicolaou (PAP) smear test screen‐
ing has decreased the incidence of cervical cancer by approximately 70% in recent decades;
however, cervical cancer still represents a major public health issue in Latin America be‐
cause of the failure of prevention programs [20].
Cervical cancer is the third most common malignancy in women worldwide and the second
most common malignancy in women living in developing countries. More than 85% of the
global burden occurs in developing countries. Cervical cancer accounts for 13% of all female
cancers, and South America is a high-risk region (2.5%); approximately 88% of deaths occur
in developing countries. These differences between countries are believed to reflect protec‐
tion through screening, differences in exposure to HPV and other cofactors. HPV is associat‐
ed with 68,220 new cases of cervical cancer and 31,712 associated cervical cancer deaths in
Latin America each year [21]. Cervical cancer is a major public health problem in Latin
America, which has some of the highest incidence and mortality rates worldwide. Informa‐
tion on HPV prevalence and type distribution in several countries in Latin America is cru‐
cial to predict the future impact of HPV16/18 vaccines and screening programs and to
establish appropriate post-vaccine virological surveillance.
The discovery of HPV infection as a necessary cause of cervical cancer has created many
new paths for prevention. The most promising strategies include screening for infection
with HR-HPV types and immunization to prevent infection with HR-HPV types. Unfortu‐
nately, many developing countries that have invested in screening programs have yet to
witness a substantial reduction in cervical cancer [22]. HPV DNA testing has been suggested
as an alternative to primary screening; HPV DNA testing is less dependent on the quality of
personnel training [23-26]. Prophylactic HPV vaccination, which currently protects against
the most common LR-HPV types (HPVs 6 and 11) and HR-HPV types (HPVs 16 and 18), of‐
fers the greatest potential to reduce the burden of ICC and other HPV-related diseases [1]. In
many of the nations where the burden of HPV and cervical cancer is the highest, vaccination
and HPV testing remain too expensive.
Current Topics in Public Health360
In this chapter, we will discuss HPV infection and provide data on HPV prevalence and
genotype distribution, risk factors for HPV infection, co-factors associated with HSIL or ICC
progression, the burden of cervical cancer and prevention strategies. All of these topics will
be discussed in the context of Latin America. We hope that this chapter will provide re‐
searchers with important up-to-date information concerning the problem of HPV infection
and HPV-associated cancers in Latin America.
2. HPV prevalence and genotype distribution
The establishment of the etiologic role of HPV on cervical cancer and the development of
proposals for preventive and clinical applications have prompted considerable interest in
exploring the epidemiological characteristics of HPV infection in different populations.
Worldwide,  there  are  important  variations  in  the  prevalence  of  HPV  in  different  age
groups.  Although in  the  United States,  Europe,  and some Asian countries,  HPV preva‐
lence declines with age [27-30], in Latin American countries, the majority of studies with
age-specific  HPV  prevalence  data  have  shown  a  slight  U-shaped  curve  [31].  Overall,
HPV prevalence in the Latin American and Caribbean (LAC) population has been found
to  be  2-fold  higher  than the  average  worldwide prevalence  [32].  Different  studies  from
countries  in Latin America have assessed the prevalence of  HPV infection and types in
healthy  women  [33]  and  patients  with  pre-neoplastic  and  neoplastic  cervical  lesions
(HSIL, ICC) [20]. These studies showed prevalence rates of HPV infection of 16.1%, 82%
and 89% in  NC,  HSIL  and  ICC,  respectively.  The  most  prevalent  HPV  types  were  the
following:  NC (HPV-16,  31,  18,  58,  and 6),  HSIL (HPV-16,  18,  58,  31,  and 33),  and ICC
(HPV-16, 18, 31, 45, and 33). See Tables 1 and 2.
Country More prevalent HPV types Cyto-histologicaldiagnosis HPV prevalence (%) References
Argentina 16,18,6,11,31,58
NC
LSIL
HSIL
ICC
26 - 43
33.1 - 96
71.4 - 100
100
[34 - 39]
Bolivia 6,11,26, 52,66,39
NC
LSIL
HSIL
ICC
5.9
NR
NR
NR
[40]
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Country More prevalent HPV types Cyto-histologicaldiagnosis HPV prevalence (%) References
Brazil 16,18,33,6,11,58
NC
LSIL
HSIL
ICC
12 - 25
26.4 - 90.4
57 - 100
41.8 - 93
[41 - 50]
Chile 16,18,31,33,45,52
NC
LSIL
HSIL
ICC
11.2 - 40
61.2 - 100
55.9 - 100
71 - 95
[51 - 58]
Colombia 16,18,31,58,33,45
NC
LSIL
HSIL
ICC
10.5 - 39.1
46.9 - 83.9
53.8 – 91.8
70 - 100
[10, 59 - 64]
Ecuador 16,31,18,6,52,56
NC
LSIL
HSIL
ICC
20 - 20.6
44.8 - 76.9
50 - 100
81
[65 - 68]
Paraguay 16,18,33,31,45, 52
NC
LSIL
HSIL
ICC
25
68
78
97
[69 - 71]
Perú 16,18,31,35,45,52
NC
LSIL
HSIL
ICC
13.4 - 17.7
NR
NR
92 - 95.3
[72, 73]
Venezuela 16,18,33,45,52,58
NC
LSIL
HSIL
ICC
NR
68
92.8 - 95.3
98.7 - 98.9
[74, 75]
Table 1. HPV prevalence and more frequent HPV types in South America.
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Country More prevalent HPV types Cyto-histologicaldiagnosis
HPV prevalence
(%) References
Costa Rica 16,18,58,31,33
NC
LSIL
HSIL
ICC
11 - 22.4
73 - 80.9
87.5 - 89
88 - 97.1
[76, 77]
Cuba 16,31,52,66,18
NC
LSIL
HSIL
ICC
NR
33.3
55.6
NR
[78]
Guatemala 16,18,56,66,35
NC
LSIL
HSIL
ICC
33.6 - 59
NR
NR
82.6 – 95.2
[79]
Honduras 16,18,31,58,45,11,51
NC
LSIL
HSIL
ICC
39.5 - 51
47.7 - 81
66.7 - 97
80 - 93
[80 - 83]
Mexico 16,18,31,58,45,59
NC
LSIL
HSIL
ICC
8.8 - 40.9
24 - 94.5
29.4 - 93.7
84.6 - 100
[28, 84 - 91]
Nicaragua 16,58,31,52,51
NC
LSIL
HSIL
ICC
48.1
67.5
86.8
94.7
[92]
Panama 16a
NC
LSIL
HSIL
ICC
NR
NR
NR
70
[93]
Table 2. HPV prevalence and more frequent HPV types in Central America and Mexico.
a Only HPV 16 was detected.
3. Risk factors for HPV infection and co-factors associated with HSIL or
ICC progression
Epidemiological studies investigating risk factors for HPV infection have clearly and con‐
sistently  shown that  sexual  behavior  patterns  influence  the  acquisition  of  HPV because
Burden of Human Papillomavirus Infection in Latin America
http://dx.doi.org/10.5772/53662
363
the  primary  mode  of  transmission  of  HPV  is  sexual.  Sexual  behavior  patterns  include
early age at first sexual intercourse, the number of sexual partners, and the sexual behav‐
ior of male partners [32].
Almost all cases of cervical cancer are attributable to persistent HPV infections, leading to
the conclusion that HPV infection is a necessary cause of the disease [94]. Follow-up studies
of women with and without cervical abnormalities have indicated that the continuous pres‐
ence of HR-HPV is necessary for the development, maintenance and progression of cervical
intraepithelial neoplasia (CIN) [9-13]. However, only a small fraction of women with cervi‐
cal HPV infection develop ICC, suggesting that other co-factors in addition to HPV are nec‐
essary to cause cancer progression. High parity, the long-term use of oral contraceptives,
cigarette smoking, and co-infection with human immunodeficiency virus (HIV) have been
described [32].
Tables 3 and 4 describe the co-factors associated with HPV infection and co-factors asso‐
ciated with HSIL or ICC progression in several studies from Central and South America,
respectively.
Country Co-factors Reference
Argentina
Number of sexual partners, C. trachomatis infection or history of
previous sexually transmitted diseases, early age at first
intercourse, early age at first pregnancy.
[35, 36, 38, 95]
Brazil Marital status, age under 30, number of sexual partners, sexuallytransmitted diseases, alcohol abuse, sexual behavior. [49,96]
Colombia
Number of sexual partners, indigenous ethnicity, no history of
previous pregnancies, nulliparity, early age at first intercourse, C.
trachomatis infection, high parity.
[97 - 99]
Costa Rica High vaginal pH, C. trachomatis infection, number of sexualpartners. [77, 100]
Cuba Parity, early age at first sexual intercourse. [78]
Ecuador Number of sexual partners. [66]
Guatemala Occasional partner during the last 6 months and smoking habit. [79]
Honduras Sexual behavior, smoking, exposure to wood smoke and lowsocioeconomic status, single female. [82, 83, 101, 102]
Mexico
Age, marital status, number of sexual partners, infection with C.
trachomatis, progesterone-based contraceptives, history of
sexually transmitted diseases and use of emergency contraceptive
pill.
[28, 103, 104]
Peru Early age at first sexual intercourse and number of sexual partners. [105]
Table 3. Co-factors associated with HPV infection in Latin America.
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Country Co-factors Reference
Brazil
Agea, ethnicityb, early age at first sexual intercoursec, number of
sexual partnersd, history of sexually transmitted diseases or
concurrent sexually transmitted diseasee, smoking habitf, C.
trachomatis infectiong.
[41, 44, 106, 107]
Colombia Parityh, exposure to wood smokei, viral loadj. [61, 108]
Costa Rica Number of live births
k, use of oral contraceptivesl and smoking
habitf. [109]
Honduras
Number of sexual partnersd, parityh, early age at first sexual
intercoursec, exposure to wood smokei, low socioeconomic
statusm, absence of Pap smear screeningn.
[80, 82]
Mexico Age
a, early age at first sexual intercoursec, number of sexual
partners, parityh, viral loadj. [84, 88, 110]
Panama Early age at first sexual intercourse
c, parityh, absence of Pap smear
controlsn, smoking habitf. [93]
Paraguay Parity
h, early age at first intercoursec, no schoolingo, number of
sexual partnerd and absence of Pap smear screeningn. [69]
Peru
Parityh, agea, no schoolingo, lack of good-quality screening and of
adequate follow-up carep, long-term use of oral contraceptivesq
and smoking habitf.
[72, 105]
Measures of risk (OR or RR) and their corresponding 95% CI and reference.
a OR 231 [25,48-2108,63] Ref 41; OR 2,1 [1,1-4,1] Ref 110.
b OR 5,77 [2,76-12,09] Ref 41.
c OR 6,83 [1,46-32,02] Ref 41; OR 1,26 [0,76-2,08] Ref 82; OR 2,11 [1,2-3,6] Ref 110; OR 8,5 [4,4-16,8] Ref 84; OR 1,91
[1,2-3] Ref 93; OR 7,8 [3,4-17,7] Ref 69.
d OR 5,43 [2,58-11,40] Ref 41; OR 2,25 [1,32-3,82] Ref 82; OR 7,4 [3,8-14,5] Ref 69.
e OR 13 [1,9-56,3] Ref 44, 106.
fOR 11,24 [5,09-24,83] Ref 41; RR 2,7 [1,1-6,7] Ref 109; OR 1,86 [1,1-3,1] Ref 93.
g OR 2,1 [1,1-4] Ref 107.
h OR 4,1 [1,6-10,6] Ref 108; OR 6,3 [1,36-2,98] Ref 80; OR 10,9 [2,6-46,5] Ref 84; OR 1,87 [1,2-3] Ref 93; OR 9,3
[3,6-23,9] Ref 69; OR 8,3 [1-65,6] Ref 105; OR 6,5 [1,1-6,93] Ref 72.
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i OR 7,3 [3-19,4] Ref 108; OR 4,89 [0,51-47,1] Ref 80.
j OR 13,4 [2,4-74] Ref 61; OR 3,51 [2,2-5,6] Ref 110; OR 365,8 [94,7-1412] Ref 88.
k RR 3,7 [1,8-7,4] Ref 109.
l RR 1,6 [0,89-2,9] Ref 109.
m OR 1,8 [1,2-2,5] Ref 82.
n OR 2,31 [1,16-4,63] Ref 82; OR 2,88 [1,8-4,5] Ref 93; OR 23,9 [10,4-54,9] Ref 69.
o OR 27,7 [9,6-79,9] Ref 69; OR 3,2 [1,3-8,3] Ref 105.
p OR 29,4 [3,6-240,1] Ref 105.
q OR 2,6 [0,9-7,6] Ref 72.
Table 4. Co-factors associated with HSIL or ICC progression in Latin America.
4. Burden of cervical cancer
After breast and colorectal cancer, cervical cancer is the third leading cancer site worldwide,
and it is second among women. The incidence of cervical cancer in Latin America is among
the highest in the world. Cervical cancer incidence and mortality are a significant public
health problem. In total, 85% of the global burden of cervical cancer occurs in developing
countries, where it accounts for 13% of all female cancers. South America is a region of high
risk. In 2008, cervical cancer was responsible for 275,000 deaths, 31,400 in Latin America and
the Caribbean [21].
In Latin American countries, the incidence and mortality of ICC ranges from 14.4 to 39.9 and
6.8 to 20.6 cases per 100,000 women, respectively, with the highest incidence and mortality
rates in Nicaragua (39.9 and 20.6, respectively, Table 5). The data were taken fron Globocan
(http://globocan.iarc.fr/factsheets/cancers/cervix.asp). These differences between countries
are most likely a reflection of screening programs and differences in exposure to HPV and
other cofactors.
5. Prevention strategies
Cervical cancer caused by HPV is a major public health problem that can be prevented with
cervical cancer screening programs. Public health programs for cervical cancer screening
with cytology and the effective treatment of early pre-cancers and cancers have resulted in a
major reduction in mortality from cervical cancer. Unfortunately, cervical cancer screening
programs have not yet been successful in most developing countries [111], despite the high‐
est burden of cervical cancer in these countries [21].
In Colombia, supply problems are found in cervical cancer in therms of structure, processes
and results [112]. The follow-up for women with abnormal cytology has not been carried
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out, information systems are insufficient, and problems in the quality of cytology readings
have been reported ( [112, 113]. These deficiencies explain, in part, the low impact that
screening has had on cervical cancer in Colombia, and the national screening and diagnostic
services offered are not organized into a structured program [112].
Country Incidence rate(per 100,000 women)
Mortality rate
(per 100,000 women)
Argentina 17.5 7.4
Bolivia 36.4 16.7
Brazil 24.5 10.9
Chile 14.4 6.6
Colombia 21.5 10.0
Costa Rica 17.5 6.7
Cuba 23.1 8.9
Ecuador 27.1 13.3
Guatemala 30.5 15.2
Honduras 37.8 19.7
Nicaragua 39.9 20.6
Panama 25.3 12.6
Paraguay 35.0 16.6
Peru 34.5 16.3
Uruguay 16.5 6.8
Venezuela 31.4 14.4
Table 5. Incidence and mortality rates for ICC in Latin America.
To screen successfully in LAC, the screening programs must follow the requirements of low-
resource settings: screening, diagnosis and treatment provided on-site or in clinics accessible
to the majority of at-risk women; a low-cost, low-technology screening test that can lead to
the immediate treatment of abnormalities; wide coverage of at-risk women; appropriate ed‐
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ucational programs directed toward health workers and women to ensure correct imple‐
mentation and high participation; and a built-in mechanism for evaluation of the screening
program [22].
With the advent of newer technology, such as HPV vaccines and HPV tests, followed by
simple well-known techniques, such as Pap, VIA and cryotherapy, cervical cancer rates may
start to decrease worldwide. Prophylactic HPV vaccines containing oncogenic types HPV-16
and 18 can prevent up to 65–70% of cervical cancer deaths. However, they have yet to be‐
come accessible to poorer countries, where the greatest burden of disease exists. The price
per dose is expensive for use in most countries in LAC. This situation is extremely disap‐
pointing because the experience of resource-poor countries in LAC has demonstrated that
vaccination programs have been very effective. The results from different countries in Latin
America have indicated that HPV testing has a greater sensitivity to detect CIN 2/3 and ICC
than the Pap test [114-116], and HPV typing is an inexpensive and effective method for iden‐
tifying cervical neoplasia and women at risk of developing cervical neoplasia; HPV typing
improves quality control for both false-negative and false-positive cytology results [117].
The screening guidelines of the American College of Obstetricians and Gynecologists indi‐
cate that if HPV testing is used in combination with Pap smears, women who are negative
for both tests should return to be tested in three years [35]. This strategy minimizes unneces‐
sary follow-up visits and invasive procedures without compromising the detection of dis‐
ease. This scheme is more appropriate for communities with limited access to public health
services, such as countries in Latin America.
Different studies in countries in Latin America have described recommendations for suc‐
cessful screening programs, such as greater HPV education of the public and health care
practitioners [118]; educational interventions for physicians in screening and management
norms [119]; the implementation of sex education in schools and the promotion of condom
use and an organized screening program to prevent cervical cancer in young women [120]; a
screening program with high follow-up rates, not only high coverage [121]; and behavioral
measures, including delaying sexual intercourse and the regular use of latex condoms [66].
HPV information is complex, and many women remain confused after reading educational
materials; thus, it is important to ensure that HPV information is accessible to people at all
levels [23].
The Regional Strategy for Comprehensive Cervical Cancer Prevention and Control proposes
to improve country capacity for the sustained implementation of comprehensive cervical
cancer prevention and control programs, with the goal of reducing incidence and mortality.
It promotes an integrated package of services for health information and education; screen‐
ing of asymptomatic women and pre-cancer treatment (improving the quality of screening
tests; considering introducing HPV DNA testing to triage HPV-positive women for further
testing; increasing the screening coverage of women in the at-risk age group (>30 years); and
increasing the proportion of timely and appropriate follow-up care for women with abnor‐
mal screening test results); invasive cervical cancer treatment and palliative care; and evi‐
dence-based policy decisions on whether and how to introduce HPV vaccines [122].
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6. Conclusion
Cervical HPV infection is the most prevalent sexually transmitted disease. HPV is so com‐
mon that more than half of all sexually active adults will be infected in their lifetime, al‐
though young, sexually active women bear the brunt of both infection and clinical
complications. The Centers for Disease Control estimates that at least half of all sexually ac‐
tive individuals will acquire HPV at some point in their lives, whereas at least 80% of wom‐
en will acquire an HPV infection by age 50. At least 50% of men will acquire a genital HPV
infection during their lifetime. In developed countries, PAP smear test screening has de‐
creased the incidence of cervical cancer by approximately 70% in recent decades; however,
cervical cancer still represents a major public health issue in Latin America and the Carib‐
bean because of the failure of prevention programs.
Cervical cancer is a major public health problem in Latin America, which has some of the
highest incidence and mortality rates worldwide. Information on HPV prevalence and type
distribution in several countries in Latin America is crucial to predict the future impact of
HPV16/18 vaccines and screening programs and to establish appropriate post-vaccine viro‐
logical surveillance, primarily with the information obtained from high-grade cervical le‐
sions and invasive cervical cancer.
Ultimately, the integration of screening with prophylactic HPV vaccination, which currently
protects against the most common LR-HPV types (HPVs 6 and 11) and HR-HPV types
(HPVs 16 and 18), offers the greatest potential to reduce the burden of ICC and other HPV-
related diseases. Unfortunately, for many of the nations where the burden of HPV and cervi‐
cal cancer is the highest, vaccination and HPV testing remain too expensive. Fortunately, the
Pan American Health Organization Revolving Fund for vaccine purchase will allow vaccine
prices to be reduced, and the vaccine would be available for free in most Latin American
countries. The implementation of HPV vaccination will have a great impact on the reduction
of the incidence and mortality of HPV-associated cancers.
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Nomenclature
CIN - Cervical intraepithelial neoplasia.
LSIL- Low-grade intraepithelial lesions.
HSIL – High-grade intraepithelial lesions.
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NC- Normal cytology.
ICC Invasive cancer cervical
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